Therapeutic efficacy of magnesium oxide for peripheral artery disease among patients undergoing hemodialysis - Open label randomized controlled trial
Not Applicable
- Conditions
- Peripheral artery disease
- Registration Number
- JPRN-UMIN000024275
- Lead Sponsor
- Department of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with serum magnesium levels of 3.4 mg/dL or greater. 2. Patients who had experienced side effects by magnesium oxide or rebamipide. 3. Patients currently taking magnesium oxide. 4. Patients suffering from critical limb ischemia. 5. Patients currently taking part in other interventional studies.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method skin perfusion pressure
- Secondary Outcome Measures
Name Time Method ankle brachial index capillary analysis system bone turnover markers (bone alkaline phosphatase, TRACP-5b, parathyroid hormone)